Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma

References

• Feugier P, Brice P, Maynadie M, et al. Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study. Leuk Lymphoma. 2018 Feb 28;1–4. doi: 10.1080/10428194.2018.1434878. [Epub ahead of print].
   PubMedGoogle Scholar
• Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2008 Sep 20;26(27):4473–4479.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2005 May 20;23(15):3383–3389.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1081–1093.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2010 Jun 10;28(17):2853–2858.
   PubMed Web of Science ®Google Scholar
• Trneny M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016 Mar;17(3):319–331.
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017 Nov;179(3):430–438.
   PubMed Web of Science ®Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211–1223.
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559–1563.
   PubMed Web of Science ®Google Scholar
• Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 Nov 2;10(1):171.
   PubMedGoogle Scholar
• Gopal AK, Kahl BS, de vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13;370(11):1008–1018.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2017 Dec 10;35(35):3898–3905.
   PubMed Web of Science ®Google Scholar
• Brown JR, Hamadani M, Hayslip J, et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr;5(4):e170–e180.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Flinn IW, Patel MR, et al. Umbralisib, a novel PI3Kdelta and casein kinase-1epsilon inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol. 2018 Apr;19(4):486–496.
   PubMed Web of Science ®Google Scholar
• Andorsky D, Yacoub A, Melear J, et al. Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: analysis of patients with double-refractory or early relapsed follicular lymphoma (FL). J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2017 abstr;35:7502.
   Web of Science ®Google Scholar
• Casulo C, Friedberg JW, Ahn KW, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a national lymphocare study and center for international blood and marrow transplant research analysis. Bio Blood Marrow Transplant. 2018 Jun;24(6):1163–1171. doi:10.1016/j.bbmt.2017.12.771.
   PubMed Web of Science ®Google Scholar
• Sureda A, Zhang MJ, Dreger P, et al. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the lymphoma working party of the EBMT and the lymphoma committee of the CIBMTR. Cancer. 2018 Apr 15;124(8):1733–1742. doi:10.1002/cncr.31264.
   Google Scholar
• Colosia A, Njue A, Trask PC, et al. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343–355. e346.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clinical Oncology: Official Journal Am Soc Clin Oncol. 2011 Nov 1;29(31):4079–4087.
   PubMed Web of Science ®Google Scholar
• Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015 Feb 26;125(9):1394–1402.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015 Jun;16(6):704–715.
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: current controversies and advances. Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):277–284.
   PubMedGoogle Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell Lymphoma. Blood. 2017;130(Suppl 1):577.
   Google Scholar
• Slawsky KA, Goss TF, Shinkle R, et al. Economic burden of relapsed/refractory diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL): a review of the literature. J Clin Oncol. 2010;28(15_suppl):e18564–e18564.
   Web of Science ®Google Scholar